[cyclobutylidene(ethoxy)methoxy](trimethyl)silane | 31469-20-2

• 分子结构分类: 有机化合物 - 有机金属化合物 - 有机类金属化合物
• 英文名称: [cyclobutylidene(ethoxy)methoxy](trimethyl)silane
• 英文别名: (cyclobutylidene(ethoxy)methoxy)trimethylsilane；[cyclobutylidene(ethoxy)methoxy]-trimethylsilane
• CAS: 31469-20-2
• 化学式: C₁₀H₂₀O₂Si
• 分子量: 200.353
• InChiKey: YVDAZQRZRHZLOM-UHFFFAOYSA-N

物化性质

• 沸点：
  207.7±23.0 °C(Predicted)
• 密度：
  0.950±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.27
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  三甲基氯硅烷 、 1,1-环丁烷-乙二酸二乙酯 在 sodium 作用下， 生成 [cyclobutylidene(ethoxy)methoxy](trimethyl)silane
  参考文献：
  名称：

  丙二酸酯和草酸酯的金属还原。双取代丙二酸酯的便捷脱羧途径和缩酮缩醛的合成

  摘要：

  二取代丙二酸酯的碱金属还原或在三甲基氯硅烷存在下用碱处理酯类可得到高产率的反应性二取代缩酮烷基三甲基甲硅烷基缩醛，而草酸二乙酯在类似条件下可还原为1,2-二乙基-1,2-双（三甲基甲硅烷氧基）乙烯。

  DOI：

  10.1039/c29710000136

文献信息

• MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF
  申请人：Weinstein David S.

  公开号：US20090075995A1

  公开（公告）日：2009-03-19

  Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity, including inflammatory and immune diseases, having the structure of formula (I): an enantiomer, diastereomer, or tautomer thereof, or a prodrug ester thereof, or a pharmaceutically-acceptable salt thereof, in which: Z is heterocyclo or heteroaryl; A is a 5- to 8-membered carbocyclic ring or a 5- to 8-membered heterocyclic ring; B is a cycloalkyl, cycloalkenyl, aryl, heterocyclo, or heteroaryl ring, wherein each ring is fused to the A ring on adjacent atoms and optionally substituted by one to four groups which are the same or different and are independently selected from R 5 , R 6 , R 7 , and R 8 ; J 1 , J 2 , and J 3 are at each occurrence the same or different and are independently -A 1 QA 2 -; Q is a bond, O, S, S(O), or S(O) 2 ; A 1 and A 2 are the same or different and are at each occurrence independently selected from a bond, C 1-3 alkylene, substituted C 1-3 alkylene, C 2-4 alkenylene, and substituted C 2-4 alkenylene, provided that A 1 and A 2 are chosen so that ring A is a 5- to 8-membered carbocyclic or heterocyclic ring; R 1 to R 11 are as defined herein. Also provided are pharmaceutical compositions and methods of treating inflammatory- or immune-associated diseases and obesity and diabetes employing said compounds.

  提供了一种新型的非甾体化合物，其在治疗与糖皮质激素受体、AP-1和/或NF-κB活性调节相关的疾病方面具有用途，包括炎症和免疫性疾病，其结构为公式(I)：其对映异构体、顺反异构体或互变异构体，或其前药酯或其药学上可接受的盐，其中：Z是杂环或杂芳基；A是5-至8-成员的碳环或5-至8-成员的杂环；B是环状烷基、环状烯基、芳基、杂环、或杂芳基，其中每个环在相邻原子上与A环融合，并可选地被一个到四个基团取代，所述基团为R5、R6、R7和R8，这些基团相同或不同，且独立地选择；J1、J2和J3在每次出现时相同或不同，并独立地为-A1QA2-；Q是键、O、S、S（O）或S（O）2；A1和A2在每次出现时相同或不同，并独立地从键、C1-3烷基、取代的C1-3烷基、C2-4烯基和取代的C2-4烯基中选择，前提是A1和A2被选择为环A是5-至8-成员的碳环或杂环；R1至R11如本文所定义。还提供了制药组合物和使用该化合物治疗炎症或免疫相关疾病以及肥胖症和糖尿病的方法。
• Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
  申请人：Bristol-Myers Squibb Company

  公开号：US08034940B2

  公开（公告）日：2011-10-11

  Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity, including inflammatory and immune diseases, having the structure of formula (I): an enantiomer, diastereomer, or tautomer thereof, or a prodrug ester thereof, or a pharmaceutically-acceptable salt thereof, in which: Z is heterocyclo or heteroaryl; A is a 5- to 8-membered carbocyclic ring or a 5- to 8-membered heterocyclic ring; B is a cycloalkyl, cycloalkenyl, aryl, heterocyclo, or heteroaryl ring, wherein each ring is fused to the A ring on adjacent atoms and optionally substituted by one to four groups which are the same or different and are independently selected from R5, R6, R7, and R8; J1, J2, and J3 are at each occurrence the same or different and are independently -A1QA2-; Q is a bond, O, S, S(O), or S(O)2; A1 and A2 are the same or different and are at each occurrence independently selected from a bond, C1-3alkylene, substituted C1-3alkylene, C2-4alkenylene, and substituted C2-4alkenylene, provided that A1 and A2 are chosen so that ring A is a 5- to 8-membered carbocyclic or heterocyclic ring; R1 to R11 are as defined herein. Also provided are pharmaceutical compositions and methods of treating inflammatory- or immune-associated diseases and obesity and diabetes employing said compounds.

  提供了新型非甾体化合物，其在治疗与葡萄糖皮质激素受体、AP-1和/或NF-κB活性调节相关的疾病方面具有用途，包括炎症和免疫疾病，其具有以下结构（I）的构造： 其中，Z是杂环或杂环芳基；A是5-至8-成员的碳环或5-至8-成员的杂环；B是环烷基，环烯基，芳基，杂环芳基或杂环，其中每个环在相邻原子上与A环融合，并且可选地被一个到四个相同或不同的基团取代，这些基团是独立地从R5、R6、R7和R8中选择的；J1、J2和J3在每次出现时相同或不同，并且独立地是-A1QA2-；Q是键，O，S，S（O）或S（O）2；A1和A2在每次出现时相同或不同，并且独立地从键，C1-3烷基，取代的C1-3烷基，C2-4烯基和取代的C2-4烯基中选择，前提是A1和A2被选择为环A是5-至8-成员的碳环或杂环；R1到R11如本文所定义。 还提供了制药组合物和使用所述化合物治疗炎症或免疫相关疾病以及肥胖症和糖尿病的方法。